COPD
MCID: PLM129
MIFTS: 73

Pulmonary Disease, Chronic Obstructive (COPD)

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 56 74 73 43 37
Chronic Obstructive Pulmonary Disease 12 74 36 29 6 3 15 62 17
Copd 56 12 73 42 3 62
Chronic Obstructive Lung Disease 12 73 15
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 56 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 29 6
Chronic Obstructive Airway Disease 12 71
Pulmonary Disease, Obstructive, Chronic, Susceptibility to 39
Severe Early-Onset Chronic Obstructive Pulmonary Disease 73
Chronic Obstructive Pulmonary Disease of Horses 71
Pulmonary Disease Chronic Obstructive 54
Upper Respiratory Infections 71
Common Cold 71
Cold 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3083
OMIM 56 606963
KEGG 36 H01714
MeSH 43 D029424
NCIt 49 C3199
SNOMED-CT 67 13645005
UMLS 71 C0009443 C0024117 C0041912 more

Summaries for Pulmonary Disease, Chronic Obstructive

KEGG : 36 Chronic obstructive pulmonary disease (COPD) is a representative chronic inflammatory disorder of the lungs that includes chronic bronchitis and emphysema. COPD is characterized by airway inflammation and progressive airflow obstruction, most commonly caused by cigarette smoking. The major symptoms of which patients complain are cough, breathlessness, and sputum production. COPD is associated with underlying inflammation in response to chronic exposure to noxious particulates and gases and with a number of comorbid conditions. The onset of COPD generally occurs in the 6th to 8th decades of life. Early onset COPD is defined as disease onset before the age of 50 years, irrespective of smoking history. The presence of persons with early onset, severely reduced pulmonary function suggests that individuals may vary in their genetic susceptibility to the effects of smoking. Alpha-1-antitrypsin deficiency is the only proven genetic risk factor for COPD. Bronchodilators are the mainstay of treatment since they improve lung function and reduce acute exacerbations. Long-acting inhaled bronchodilators are recommended as first line treatment for patients with persistent symptoms.

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to pleural disease and asthma, and has symptoms including tremor, fever and angina pectoris. An important gene associated with Pulmonary Disease, Chronic Obstructive is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and IL-1 Family Signaling Pathways. The drugs mometasone furoate and Caspofungin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotype is chronic obstructive pulmonary disease.

OMIM : 56 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

MedlinePlus : 42 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Chronic obstructive pulmonary disease, or COPD, refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis.

UniProtKB/Swiss-Prot : 73 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 62 About chronic obstructive pulmonary disease: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time. COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms. Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 74 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1803)
# Related Disease Score Top Affiliating Genes
1 pleural disease 33.5 TNF CXCL8 CRP
2 asthma 32.9 TNF SERPINA3 SERPINA1 PDE4A MUC5AC MMP12
3 granulomatosis with polyangiitis 32.8 TNF SERPINA1 ELANE CRP
4 blood group, globoside system 32.7 TNF CXCL8 CRP
5 bronchitis 32.4 TNF SERPINA1 MMP12 ELANE CXCL8 CRP
6 lung disease 32.2 TNF SERPINA3 SERPINA1 PDE4A MUC5AC HMOX1
7 respiratory failure 31.9 TNF SERPINA3 SERPINA1 PDE4A MUC5AC ELANE
8 cystic fibrosis 31.9 TNF SERPINA1 MUC5AC HMOX1 ELANE CXCL8
9 pneumothorax 31.9 SERPINA1 MMP1 HMOX1
10 pulmonary hypertension 31.8 TNF PDE4A HMOX1 ELANE CXCL8 CRP
11 pulmonary emphysema 31.8 SERPINA3 SERPINA1 MMP12 MMP1 HMOX1 ELANE
12 pneumonia 31.7 TNF SERPINA1 MMP12 HMOX1 ELANE CXCL8
13 atherosclerosis susceptibility 31.7 TUG1 TNF CXCL8 CRP
14 chronic ulcer of skin 31.7 TNF MMP1 ELANE CRP
15 pulmonary edema 31.7 TNF HMOX1 CXCL8 CRP
16 bronchiectasis 31.6 TNF SERPINA3 SERPINA1 ELANE CXCL8 CRP
17 apnea, obstructive sleep 31.6 TNF CXCL8 CRP
18 nasopharyngitis 31.6 TNF PDE4A CRP
19 bronchial disease 31.6 TNF SERPINA3 PDE4A MUC5AC ELANE CXCL8
20 bronchiolitis 31.6 TNF MUC5AC CXCL8 CRP
21 lung cancer susceptibility 3 31.6 TUG1 SERPINA3 SERPINA1 MUC5AC MEG3 HMOX1
22 common cold 31.6 TNF MUC5AC CXCL8
23 alpha-1-antitrypsin deficiency 31.6 TNF SERPINA3 SERPINA1 MMP12 ELANE CXCL8
24 peripheral artery disease 31.5 TNF HMOX1 CRP
25 peripheral nervous system disease 31.5 TNF SERPINA3 CXCL8 CRP
26 skin disease 31.5 TNF SERPINA3 PDE4A MMP1 CXCL8 CRP
27 bronchiolitis obliterans 31.5 TNF CXCL8 CRP
28 diabetes mellitus 31.5 TUG1 TNF SERPINA1 MEG3 HMOX1 CXCL8
29 respiratory allergy 31.4 TNF MUC5AC CXCL8
30 eye disease 31.4 TNF SERPINA3 SERPINA1 MUC5AC MMP1 CXCL8
31 rheumatoid arthritis 31.4 TNF SERPINA3 MMP12 MMP1 ELANE CXCL8
32 myeloma, multiple 31.4 TUG1 TNF MEG3 CXCL8 CRP
33 inflammatory bowel disease 31.4 TNF PDE4A MUC5AC MMP1 HMOX1 ELANE
34 carotid stenosis 31.4 TNF MMP1 CXCL8 CRP
35 periodontitis 31.4 TNF MMP1 ELANE CXCL8 CRP
36 liver disease 31.4 TNF SERPINA3 SERPINA1 MEG3 CXCL8
37 severe cutaneous adverse reaction 31.4 TNF MUC5AC CRP
38 systolic heart failure 31.3 TNF MMP1 CRP
39 sleep apnea 31.3 TNF CXCL8 CRP
40 exanthem 31.3 TNF CXCL8 CRP
41 pneumoconiosis 31.2 TNF SERPINA1 CXCL8
42 peritonitis 31.2 TNF ELANE CXCL8 CRP
43 peptic ulcer disease 31.2 TNF MUC5AC CXCL8
44 status asthmaticus 31.2 MUC5AC ELANE CXCL8
45 dermatitis, atopic 31.2 TNF SERPINA3 PDE4A MUC5AC CXCL8
46 pulmonary fibrosis, idiopathic 31.2 TNF MMP12 MMP1 ELANE CXCL8 CRP
47 endocarditis 31.2 TNF CXCL8 CRP
48 toxic shock syndrome 31.2 TNF CXCL8 CRP
49 haemophilus influenzae 31.2 TNF CXCL8
50 pulpitis 31.2 TNF MMP1 CXCL8

Comorbidity relations with Pulmonary Disease, Chronic Obstructive via Phenotypic Disease Network (PDN):


Bronchitis Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

31
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 31 HP:0006510

Clinical features from OMIM:

606963

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


tremor, fever, angina pectoris, pruritus, tinnitus, snoring, rhinorrhea, sore throat, coughing, vertigo/dizziness, equilibration disorder, catarrh, upper respiratory tract inflammation

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMed Health treatment related to Pulmonary Disease, Chronic Obstructive: 62

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease. The goals of COPD treatment include: Relieving your symptoms Slowing the progress of the disease Improving your exercise tolerance (your ability to stay active) Preventing and treating complications Improving your overall health To assist with your treatment , your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders .

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1073)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
2
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
5
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
6
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
7
Docosanol Approved, Investigational Phase 4 661-19-8, 30303-65-2 12620
8
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
9
Theophylline Approved Phase 4 58-55-9 2153
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
12
Azithromycin Approved Phase 4 83905-01-5 55185 447043
13
Fenoterol Approved, Investigational Phase 4 13392-18-2 3343
14
Norflurane Approved, Experimental Phase 4 811-97-2
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
17
Terbutaline Approved Phase 4 23031-25-6 5403
18
Fosinopril Approved Phase 4 98048-97-6 55891
19
Chlorpheniramine Approved Phase 4 113-92-8, 132-22-9 2725
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Bisoprolol Approved Phase 4 66722-44-9 2405
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
24
Sultamicillin Approved, Investigational Phase 4 76497-13-7
25
Sulbactam Approved Phase 4 68373-14-8
26
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
27
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
28
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
29
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
30
Riociguat Approved Phase 4 625115-55-1
31
Ledipasvir Approved Phase 4 1256388-51-8 67505836
32
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
33
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
34
Remifentanil Approved Phase 4 132875-61-7 60815
35
Desflurane Approved Phase 4 57041-67-5 42113
36
Montelukast Approved Phase 4 158966-92-8 5281040
37
Ticagrelor Approved Phase 4 274693-27-5 9871419
38
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
39
Dobutamine Approved Phase 4 34368-04-2 36811
40
Ribavirin Approved Phase 4 36791-04-5 37542
41
Mycophenolic acid Approved Phase 4 24280-93-1 446541
42
Iodine Approved, Investigational Phase 4 7553-56-2 807
43
Povidone Approved Phase 4 9003-39-8
44
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
45
Sucralfate Approved Phase 4 54182-58-0
46
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
47
Ondansetron Approved Phase 4 99614-02-5 4595
48
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
49
Nortriptyline Approved Phase 4 72-69-5 4543
50
Ergotamine Approved Phase 4 113-15-5 8223

Interventional clinical trials:

(show top 50) (show all 6671)
# Name Status NCT ID Phase Drugs
1 Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin Unknown status NCT00132860 Phase 4 azithromycin
2 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
3 Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD Unknown status NCT00288548 Phase 4 Metoprolol
4 An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
5 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
6 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
7 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD:a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
8 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
9 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
10 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
11 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
12 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
13 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
14 Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
15 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial Unknown status NCT02197871 Phase 4
16 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
17 Effect of Acetazolamide on Postural Control in Patients With Chronic Obstructive Pulmonary Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Unknown status NCT03177811 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
18 The Lung Attack Alert Study Unknown status NCT01107613 Phase 4
19 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
20 Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
21 The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
22 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
23 Evaluation and Treatment of Small Airways in COPD Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
24 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
25 Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
26 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
27 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
28 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
29 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
30 Advair - CRP Study Unknown status NCT00120978 Phase 4 Advair;Flovent
31 Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Unknown status NCT02787863 Phase 4 Polioxidonium
32 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
33 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
34 Randomized,Double-blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of the Phytotherapic Compound "Bromelin" on Acute Irritative Cough Unknown status NCT01356693 Phase 4 Bromelin;Placebo
35 Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT03388853 Phase 4 Acetylcysteine/Doxofylline
36 Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold. Unknown status NCT01651663 Phase 4 Arbidol (Umifenovir);Arbidol (Umifenovir)
37 Comparison of Efficacy and Safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Treatment Administered Via Capsair and Original Product Seretide Diskus 500 mcg Inhalation Powder Treatment in Patients With Moderate-severe Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT03363503 Phase 4 Salmeterol/Fluticasone Capsair®;Salmeterol/Fluticasone Diskus®
38 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
39 Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise Unknown status NCT00476736 Phase 4 Effect on small airways (N-Acetylcystein)
40 The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
41 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
42 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis Unknown status NCT02288156 Phase 4 Capsaicin;placebo
43 Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21 Unknown status NCT01498432 Phase 4 Heliox21;Air O2
44 Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
45 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
46 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype Unknown status NCT01431625 Phase 4
47 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
48 Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial Unknown status NCT02299908 Phase 4 TAP block with Bupivacaine at 0.25%;Placebo saline solution
49 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
50 Liberal Versus Restrictive Transfusion Management in Patients Being Weaned From Prolonged Mechanical Ventilation Unknown status NCT01256645 Phase 4

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ascorbic Acid
Ascorbic Acid Powder
Echinacea Preparation
Guaifenesin
indacaterol
olodaterol
Olodaterol hydrochloride
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
Pseudoephedrine
Pseudoephedrine Hydrochloride
Pseudoephedrine sulfate
Sodium Ascorbate
Zinc Acetate
zinc chloride
Zinc Gluconate
Zinc Sulfate
ZINC SULFATE PWDR

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 29 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 29

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

40
Lung, Testes, Heart, Liver, Kidney, Neutrophil, Bone

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 30219)
# Title Authors PMID Year
1
Heme oxygenase 1 variations and lung function decline in smokers: proof of replication. 56 6
18519631 2008
2
Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. 56 6
16882737 2006
3
The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. 56 6
11875051 2002
4
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. 56 6
10631150 2000
5
The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). 54 61 56
15175276 2004
6
Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. 54 61 56
14530202 2003
7
Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. 61 56
22140090 2012
8
FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. 61 56
21690325 2011
9
Variants in FAM13A are associated with chronic obstructive pulmonary disease. 61 56
20173748 2010
10
Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. 61 56
19279160 2009
11
Antielastin autoimmunity in tobacco smoking-induced emphysema. 61 56
17450149 2007
12
The SERPINE2 gene and chronic obstructive pulmonary disease. 61 56
16773582 2006
13
The SERPINE2 gene is associated with chronic obstructive pulmonary disease. 61 56
16358219 2006
14
Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease. 61 56
16278826 2006
15
Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. 61 56
12719384 2003
16
Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. 61 56
11914989 2002
17
Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study. 61 42
31764822 2019
18
Advance in sleep medicine and non-invasive ventilation in respiratory medicine. 61 42
31703528 2019
19
Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. 56
19996190 2010
20
The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. 56
19933216 2010
21
MMP12, lung function, and COPD in high-risk populations. 56
20018959 2009
22
Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. 56
19800047 2009
23
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. 56
18488036 2008
24
A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. 6
18030675 2008
25
Matrix metalloproteinase-12 gene expression in human vascular smooth muscle cells. 56
12622720 2003
26
A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. 6
11741975 2002
27
Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. 56
10807873 2000
28
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. 6
9850057 1998
29
Duaklir Pressair: another LAMA/LABA inhaler for COPD. 42
31599867 2019
30
MCP1 -2518 polymorphism and chronic obstructive pulmonary disease in Taiwanese men. 54 61
20497022 2010
31
[Role of glucocorticoid receptor and nuclear factor-kappaB in patients with stable chronic obstructive pulmonary disease]. 54 61
20450542 2010
32
Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. 54 61
20397815 2010
33
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. 54 61
20100935 2010
34
Peripheral neuropathy in chronic obstructive pulmonary disease. 54 61
20214459 2010
35
Interleukin-13: prospects for new treatments. 54 61
19878194 2010
36
Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. 54 61
19556740 2010
37
The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease. 54 61
20150838 2010
38
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. 54 61
20008877 2009
39
Il13 promoter (-1055) polymorphisms associated with chronic obstructive pulmonary disease in Taiwanese. 54 61
19995275 2009
40
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. 54 61
19775099 2009
41
[The changes and significance of interleukin-16 and CXC chemokine receptor 3 expression in pulmonary artery of smokers with chronic obstructive pulmonary disease]. 54 61
20079227 2009
42
Genetic polymorphism of GSTT1 and GSTM1 and susceptibility to chronic obstructive pulmonary disease (COPD). 54 61
19664521 2009
43
Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease. 54 61
19507017 2009
44
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. 54 61
19716960 2009
45
Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. 54 61
19410558 2009
46
Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease. 54 61
19186046 2009
47
Pharmacological modulation of Th17. 54 61
19519592 2009
48
The possible role of granzyme B in the pathogenesis of chronic obstructive pulmonary disease. 54 61
19638369 2009
49
Abnormal transition pore kinetics and cytochrome C release in muscle mitochondria of patients with chronic obstructive pulmonary disease. 54 61
19011161 2009
50
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. 54 61
19213793 2009

Variations for Pulmonary Disease, Chronic Obstructive

ClinVar genetic disease variations for Pulmonary Disease, Chronic Obstructive:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HSPA1L NM_005527.4(HSPA1L):c.1478C>A (p.Thr493Lys)SNV association 694520 rs2227956 6:31778272-31778272 6:31810495-31810495
2 HSPA1A NC_000006.12:g.31815431A>CSNV association 694515 rs1008438 6:31783208-31783208 6:31815431-31815431
3 HSPA1A NM_005345.6(HSPA1A):c.-27G>CSNV association 694516 rs1043618 6:31783507-31783507 6:31815730-31815730
4 HSPA1A NM_005345.6(HSPA1A):c.330G>C (p.Glu110Asp)SNV association 694514 rs562047 6:31783863-31783863 6:31816086-31816086
5 HSPA1A NM_005345.6(HSPA1A):c.1053G>A (p.Gln351=)SNV association 694517 rs1061581 6:31784586-31784586 6:31816809-31816809
6 HSPA1B NC_000006.12:g.31826815C>TSNV association 694519 rs2763979 6:31794592-31794592 6:31826815-31826815
7 HSPA1B NM_005346.6(HSPA1B):c.-178C>TSNV association 694518 rs6457452 6:31795550-31795550 6:31827773-31827773
8 SERPINA1 NM_001127701.1(SERPINA1):c.1096G>A (p.Glu366Lys)SNV Pathogenic 17967 rs28929474 14:94844947-94844947 14:94378610-94378610
9 SERPINA1 NM_001127701.1(SERPINA1):c.863A>T (p.Glu288Val)SNV Pathogenic 17969 rs17580 14:94847262-94847262 14:94380925-94380925
10 SERPINA1 NM_001127701.1(SERPINA1):c.194T>C (p.Leu65Pro)SNV Pathogenic/Likely pathogenic 17971 rs28931569 14:94849381-94849381 14:94383044-94383044
11 HMOX1 HMOX1, (GT)n REPEATundetermined variant risk factor 15897

Copy number variations for Pulmonary Disease, Chronic Obstructive from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 230707 8 1 12700000 Copy number DEFB4 Chronic obstructive pulmonary disease

Expression for Pulmonary Disease, Chronic Obstructive

Search GEO for disease gene expression data for Pulmonary Disease, Chronic Obstructive.

Pathways for Pulmonary Disease, Chronic Obstructive

Pathways related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 TNF MUC5AC MMP1 CXCL8
2
Show member pathways
11.91 TNF MUC5AC HMOX1 CXCL8
3 11.64 TNF MMP1 CXCL8
4 11.61 TNF MMP1 HMOX1 CXCL8
5 11.57 MMP1 HDAC2 CXCL8
6
Show member pathways
11.45 TNF MMP12 MMP1 ELANE
7
Show member pathways
11.41 TNF MMP1 CXCL8
8 11.37 MMP12 MMP1 CXCL8
9 11.06 TNF SERPINA1 HMOX1 CXCL8
10 11.03 MMP1 HMOX1 CXCL8
11 10.2 TNF HMOX1 CXCL8 CRP

GO Terms for Pulmonary Disease, Chronic Obstructive

Cellular components related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF SERPINA3 SERPINA1 MUC5AC MMP12 MMP1
2 extracellular space GO:0005615 9.28 TNF SERPINA3 SERPINA1 MUC5AC MMP12 HMOX1

Biological processes related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.37 TNF ELANE
2 extracellular matrix disassembly GO:0022617 9.33 MMP12 MMP1 ELANE
3 positive regulation of chemokine biosynthetic process GO:0045080 9.32 TNF HMOX1
4 negative regulation of lipid storage GO:0010888 9.26 TNF CRP
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.13 TNF HMOX1 ELANE
6 acute-phase response GO:0006953 8.8 SERPINA3 SERPINA1 CRP

Molecular functions related to Pulmonary Disease, Chronic Obstructive according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 MMP12 MMP1 ELANE

Sources for Pulmonary Disease, Chronic Obstructive

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....